ASCO GI: Transplant Shows Best Survival for Local Liver Cancer Therapy
ORLANDO -- If all things were equal, a new liver would offer the best chance of long term survival for hepatocellular carcinoma -- but these patients make up a heterogeneous group.
ORLANDO, Jan. 22 -- If all things were equal, a new liver would offer the best chance of long term survival for hepatocellular carcinoma.
So said Roderich Schwarz, M.D., of the Cancer Institute of New Jersey in New Brunswick, who compared survival for three local treatment strategies -- transplant, surgical resection, and ablation.
After five years, the survival rate for transplant patients was 67%, versus 38% for those who had surgical resection and 19% for ablation procedures (P
FDA Accepts Protocol for Annovis Bio’s Buntanetap Phase 3 Alzheimer Disease Trial
January 9th 2025Buntanetap is an oral molecule designed to inhibit the production of multiple neurotoxic proteins and is under investigation for treatment of Alzheimer Disease, Parkinson’s Disease, and other neurodegenerative diseases.
